65 / 210
Ponencias
65
in prophylaxis-new insight provided by pharmacokinetic modelling.
Haemophilia 2015;21(3):300-6.
18. Berntorp E, Negrier C, Gozzi P, Blaas PM, Lethagen S. Dosing
regimens, FVIII levels and estimated haemostatic protection with
special focus on rFVIIIFc. Haemophilia 2016;22(3):389-96.
19. Den Uijl IE, Fischer K, van Der Bom JG, Grobbee DE, Rosendaal
FR, Plug I. Analysis of low frequency bleeding data: the association
of joint bleeds according to baseline FVIII activity levels. Haemo-
philia 2011;17(1):41-4.
20. Uchida N, Sambe T, Yoneyama K, Fukazawa N, Kawanishi T, Koba-
yashi Set al. A first-in-human phase 1 study of ACE910, a novel
factor VIII-mimetic bispecific antibody, in healthy subjects. Blood
2016;127(13):1633-41.
21. Chowdary P, Lethagen S, Friedrich U, Brand B, Hay C, Abdul Karim
F, et al. Safety and pharmacokinetics of anti-TFPI antibody (conci-
zumab) in healthy volunteers and patients with hemophilia: a rando-
mized first human dose trial. J Thromb Haemost 2015;13(5):743-54.
22. Pasi KJ. A Subcutaneously Administered Investigational RNAi
Therapeutic (ALN-AT3) Targeting Antithrombin for Treatment of
Hemophilia: InterimWeekly and Monthly Dosing Results in Patients
with Hemophilia A or BAbstract 551 HematologyAm Soc Hematol
57th. Orlando, Florida; 2015.